furfuryl-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine | 5334-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: furfuryl-(1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine
• 英文别名: 4-(Furfurylamino)-1-methyl-1H-pyrazolo[3,4-D]pyrimidine；N-(furan-2-ylmethyl)-1-methylpyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 5334-58-7
• 化学式: C₁₁H₁₁N₅O
• mdl: MFCD05237298
• 分子量: 229.241
• InChiKey: SLSBIKJXTHGILH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  68.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] COMPOUNDS FOR IMPROVING MRNA SPLICING<br/>[FR] COMPOSÉS POUR AMÉLIORER L'ÉPISSAGE DE L'ARNM
  申请人：GEN HOSPITAL CORP

  公开号：WO2016115434A1

  公开（公告）日：2016-07-21

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供了一些有助于改善细胞内mRNA剪接的化合物。本文提供的示例化合物有助于改善包含至少一个以核苷酸序列CAA结尾的外显子的基因的mRNA剪接。还提供了制备这些化合物的方法以及治疗中枢神经系统疾病的方法。
• PYRAZOLOPYRIMIDINE ANTIBACTERIAL AGENTS
  申请人：BOARD OF TRUSTEES OF NORTHERN ILLINOIS UNIVERSITY

  公开号：US20170355700A1

  公开（公告）日：2017-12-14

  Pyrazolopyrimidine compounds for inhibition of isoprenoid biosynthesis have a formula (I) or a pharmaceutically acceptable salt thereof. In formula (I), R 1 includes an alkyl group and R 2 includes an optionally substituted moiety selected from the group consisting of an optionally substituted benzyl group, an optionally substituted phenethyl group, an optionally substituted ethanol group, an optionally substituted ethyl acetate group, an optionally substituted methyl furan group, an optionally substituted 3-ethyl indole group, and a lower alkyl group. Compositions containing pyrazolopyrimidine compounds and methods for using pyrazolopyrimidine compounds are described.

  吡唑吡咯嘧啶类化合物用于抑制异戊二烯生物合成，其化学式（I）或其药学上可接受的盐。在式（I）中，R1包括一个烷基基团，R2包括一个从可选取的苯甲基基团、可选取的苯乙基基团、可选取的乙醇基团、可选取的乙酸乙酯基团、可选取的甲基呋喃基团、可选取的3-乙基吲哚基团和较低烷基基团中选择的可选取的取代基团。描述了含有吡唑吡咯嘧啶类化合物的组合物和使用吡唑吡咯嘧啶类化合物的方法。
• Compounds for improving mRNA splicing
  申请人：The General Hospital Corporation

  公开号：US10676475B2

  公开（公告）日：2020-06-09

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.

  本文提供的化合物有助于改善细胞中的 mRNA 剪接。本文提供的示例化合物可用于改善包含至少一个以核苷酸序列 CAA 结尾的外显子的基因中的 mRNA 剪接。还提供了制备这些化合物的方法和治疗中枢神经系统疾病的方法。
• Compounds for Improving mRNA Splicing
  申请人：The General Hospital Corporation

  公开号：US20180118748A1

  公开（公告）日：2018-05-03

  Provided herein are compounds useful for improving mRNA splicing in a cell. Exemplary compounds provided herein are useful for improving mRNA splicing in genes comprising at least one exon ending in the nucleotide sequence CAA. Methods for preparing the compounds and methods of treating diseases of the central nervous system are also provided.